While Sagimet Biosciences has reported an improvement in its Q2 losses compared to the same period last year, it is still in a loss-making position. This could indicate that the company is making progress in its operations, but it's not yet profitable. The company's cash position is relatively stable, which could provide some financial stability in the short term. However, without more information on the company's future plans and market conditions, it's difficult to predict the short-term impact on the stock price.